NEW YORK (GenomeWeb) – N-of-One announced today that it has signed an agreement with molecular diagnostics company Admera Health to provide clinical interpretation for patients tested with Admera's OncoGxOne 64-gene oncology panel.
N-of-One will analyze the results of each OncoGxOne test to identify the most relevant therapeutic options for each patient based on scientific and clinical evidence. The OncoGxOne is a next-generation sequencing panel that detects 64 of the most common mutations — including SNVs, insertions and deletions, copy number variants, and gene fusions associated with all current FDA approved targeted therapies and multiple registered clinical trials — found in several cancer types.
Financial terms of the deal were not disclosed.
"We are very pleased to be able to offer N-of-One's patient-specific analysis with our OncoGxOne cancer panel," said Admera Health Lab Director James Dermody in a statement. "Admera Health's goal of easily integrating into routine clinical practice is supported by partnering with N-of-One. With N-of-One, we can provide oncologists with an Admera Health diagnostic report that is clear, actionable, and based on the latest scientific evidence."
N-of-One has signed similar deals in recent months, including a global agreement in November 2015 to provide clinical and scientific evidence that supports personalized treatment recommendations made on the basis of WuXi Nextcode's tumor-normal sequence interpretation, and a deal earlier this month to provide Macrogen with clinical interpretation services for its clinical next-generation sequencing-based cancer panels.